PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, May 3, 2024, at the Grand Hyatt Hotel in San Antonio, TX at the American Urological Association Annual Meeting from 8:00am to 9:30am Central Time.
加利福尼亞州聖何塞，2024 年 4 月 4 日（環球新聞專線）— PROCEPT BioRobotics Corporation（納斯達克股票代碼：PRCT）是一家專注於通過開發泌尿外科變革性解決方案來促進患者護理的手術機器人公司。該公司今天宣佈，將於2024年5月3日星期五中部時間上午 8:00 至上午 9:30 在德克薩斯州聖安東尼奧的君悅酒店舉行的美國泌尿外科協會年會上舉辦面對面的投資者活動。
Members of PROCEPT BioRobotics' management team presenting include:
PROCEPT BioRobotics 管理團隊出席會議的成員包括：
- Reza Zadno – President & Chief Executive Officer
- Kevin Waters – Executive VP & Chief Financial Officer
- Sham Shiblaq – Executive VP & Chief Commercial Officer
- Barry Templin – Executive VP, Technology and Clinical Development
- Reza Zadno — 總裁兼首席執行官
- 凱文·沃特斯 — 執行副總裁兼首席財務官
- Sham Shiblaq — 執行副總裁兼首席商務官
- Barry Templin — 技術和臨床開發執行副總裁
Clinical perspectives will also be provided by the following physicians:
以下醫生還將提供臨床觀點：
- Dr. Inderbir Gill, Founding Executive Director for USC Urology and Chairman of Urological Cancer Surgery at Keck School of Medicine of USC
- Dr. Brian Helfand, Division of Urology, NorthShore University Health System
-
Dr. Lewis S. Kriteman, Partner and Executive VP, Georgia Urology
- Inderbir Gill 博士，創始執行董事 南加州大學泌尿外科 兼南加州大學凱克醫學院泌尿外科主任
- 布萊恩·赫爾芬德博士，北岸大學衛生系統泌尿外科
- 喬治亞泌尿外科合夥人兼執行副總裁劉易斯·克里特曼博士
A live webcast of the event, as well as an archived recording, will be available on the "Investors" section of the Company's website at https://ir.procept-biorobotics.com/. The webcast will be archived and available for replay for at least 90 days after the event.
該活動的網絡直播和存檔錄音將在公司網站的 “投資者” 欄目上公佈，網址爲 https://ir.procept-biorobotics.com/。網絡直播將在活動結束後至少 90 天內存檔並可供重播。
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
關於 PROCEPT BioRobotics 公司
PROCEPT BioRobotics是一家手術機器人公司，致力於通過開發泌尿科變革性解決方案來促進患者護理。PROCEPT BioRobotics開發、製造和銷售AquaBeam機器人系統，這是一種先進的圖像引導手術機器人系統，用於微創泌尿外科手術，最初的重點是治療良性前列腺增生（BPH）。良性前列腺增生是最常見的前列腺疾病，在美國影響約4000萬男性。PROCEPT BioRobotics 設計的水消融療法旨在爲因良性前列腺增生引起的下尿路症狀或 LUTS 的男性提供有效、安全和持久的療效，這些症狀與前列腺大小和形狀或外科醫生的經驗無關。該公司已經開發了大量且不斷增長的臨床證據，其中包括九項臨床研究和150多份經過同行評審的出版物，這些證據支持了Aquablation療法的益處和臨床優勢。
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/.
所有手術治療都有固有的和相關的副作用。有關潛在副作用的清單，請訪問 https://aquablation.com/safety-information/。
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
投資者聯繫人：
Matt Bacso
投資者關係和業務運營副總裁
m.bacso@procept-biorobotics.com
譯文內容由第三人軟體翻譯。